Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERTA study of verteporfin photodynamic therapy with or without intravitreal triamcinolone in age-related macular degeneration
2005-001324-36Phase 3Active
- Sponsor
- Vissum, Instituto Oftalmológico de Alicante
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of verteporfin and triamcinolone acetonide in age-related macular degeneration (AMD) and Subretinal neovascularization (3 arms), sponsored by Vissum, Instituto Oftalmológico de Alicante. Primary endpoints: Mean change in visual acuity at 12 months and Difference in mean visual acuity change between groups. Started Sep 2005; status: active.
02
Drugs
verteporfintriamcinolone acetonide
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2005-001324-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001324-36.